Enject Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Out of Business

  • Latest Deal Type
  • Out of Business

Enject General Information

Description

Developer of auto-injectors designed to automatically mix the glucagon and liquid. The company's auto-injector is a two-chamber glucagon pen and a simple press of the pen to the patient's skin can inject the medicines, enabling doctors to treat severe hypoglycemia.

Contact Information

Website
www.enject.com
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 2210 West Main Street
  • Battle Ground, WA 98604
  • United States
+1 (360)
Primary Industry
Other Devices and Supplies
Other Industries
Drug Delivery
Biotechnology
Corporate Office
  • 2210 West Main Street
  • Battle Ground, WA 98604
  • United States
+1 (360)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Enject Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Out of Business 01-Aug-2016 Completed Out of Business
2. Early Stage VC 11-Sep-2009 Completed Startup
1. Early Stage VC (Series A) 08-Oct-2008 $2.55M $2.55M Completed Startup
To view Enject’s complete valuation and funding history, request access »

Enject Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A
To view Enject’s complete cap table history, request access »

Enject Patents

  • 7

    Total Documents Applications and Grants

  • Total Patents Families

  • 3

    Granted

  • Pending

  • Expiring in next 12 mo

Enject Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20140287998-A1 Glucagon formulations Inactive 09-Dec-2011
US-7655618-B2 Drugs comprising insulin and glucagon administered to control and treat diabetes while reducing or eliminating the risk of insulin-induced hypoglycemia Inactive 27-Dec-2002
US-20060014670-A1 Drugs comprising insulin and glucagon administered to control and treat diabetes while reducing or eliminating the risk of insulin-induced hypoglycemia Active 27-Dec-2002
US-20080166399-A1 Administering insulin and glucagon; liposomes; kits Active 27-Dec-2002
US-7678762-B2 Administering insulin and glucagon; liposomes; kits Inactive 27-Dec-2002 A61K38/26
To view Enject’s complete patent history, request access »

Ready to get started?

Request a free trial

Enject FAQs

  • When was Enject founded?

    Enject was founded in 2007.

  • Where is Enject headquartered?

    Enject is headquartered in Battle Ground, WA.

  • What industry is Enject in?

    Enject’s primary industry is Other Devices and Supplies.

  • Is Enject a private or public company?

    Enject is a Private company.

  • What is Enject’s current revenue?

    The current revenue for Enject is .

  • How much funding has Enject raised over time?

    Enject has raised $3.55M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »